DNMT3A

The Leukemia & Lymphoma Society Honors Five Outstanding Blood Cancer Scientists with 2023 Awards

Retrieved on: 
Lundi, décembre 11, 2023
Seattle Children's, City, ASH, Patient, Research, Biomedical Research, CRISPR, AML, Growth, Quality of life, Knowledge, LLS, Bone marrow, NCI-designated Cancer Center, Beat, Acute myeloid leukemia, Division, Dana–Farber Cancer Institute, Genome, Pancreatic serous cystadenoma, Society, DNMT3A, Face, Research institute, Lymphoma, Survivor, Network, Health, Forensic and Scientific Services, Associate, Vaccine, Chronic lymphocytic leukemia, RYE, Death, CDP, CLL, Medical device, Pharmaceutical industry, Leukemia, Medicine, Hope

Humanitarian Scientists Honored for Service to LLS, Blood Cancer Community

Key Points: 
  • Humanitarian Scientists Honored for Service to LLS, Blood Cancer Community
    The Excellence in Scientific Service award recognizes outstanding scientists who have made exceptional contributions to blood cancer research and have also generously given their time and expertise to help LLS find and fund the brightest scientists and most innovative biotech companies working to cure all forms of blood cancer.
  • "LLS is the premier organization supporting blood cancer research, and I have been privileged for the opportunity to support their efforts.
  • 2023 LLS-CDP Clinical Scholar Achievement Awardee, Matthew Davids, M.D., is Associate Professor of Medicine and Leader of the Lymphoma Program for Dana-Farber/Harvard Cancer Center.
  • LLS hosts the Research Awards & Networking Event annually timed to the American Society of Hematology (ASH) annual meeting.

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
Lundi, juin 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Retrieved on: 
Jeudi, mai 11, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, Abstract, TET2, DNA, European Hematology Association, TI, Imetelstat, Chromosome, Infection, RNA, VAF, MDS, Corporation, ASXL1, Geron Corporation, Patient, Risk, CEST, Cytopenia, EHA, Public, RS, Transfusion-associated circulatory overload, DNA methylation, Gene, Thrombocytopenia, RNA splicing, Fatigue, Pharmaceutical industry, DNMT3A, SF3B1

The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.

Key Points: 
  • The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.
  • As reported in January, 39.8% (47/118) of imetelstat-treated patients versus 15.0% (9/60) of placebo-treated patients achieved the study primary endpoint of 8-week TI (P
  • As noted in the abstract, a main therapeutic goal in lower risk MDS is to alter disease biology by eradicating malignant clones.
  • Of the 178 patients enrolled in IMerge Phase 3, 22.0% of imetelstat-treated patients and 21.7% of placebo-treated patients had baseline cytogenetic abnormalities.

Aptose Reports Results for the First Quarter 2023

Retrieved on: 
Lundi, mai 8, 2023
TP53, APS, CRH, NPM1, Aes, Food and Drug Administration, Clinical trial, G1, Absorption, Aplastic anemia, Trial of the century, Acute myeloid leukemia, Phase 1, AML, Running, Drug-related deaths in the United Kingdom, MLL, Patient, RAS, SAN, EHA, RUNX1, IDH, FLT3, TSX, CRi, Toxic leukoencephalopathy, Infrared spectroscopy correlation table, FDA, CRP, Gene, Safety, Pharmaceutical industry, DNMT3A, G3

─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;

Key Points: 
  • ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial;
    SAN DIEGO and TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for first quarter ended March 31, 2023, and provided a corporate update.
  • “While it is still too early to report confirmed responses in the APTIVATE trial, it is moving in the right direction.
  • Aptose has identified a safe therapeutic range with a broad therapeutic window, spanning the dose levels of 40, 80, 120 and 160 milligrams.
  • If findings continue as anticipated, Aptose plans to escalate the dose of G3 and seek a dose with robust safety and higher exposure levels.

Aptose Reports Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Jeudi, mars 23, 2023
ASH, Lux, APS, Controller, ITD, TKD, G1, BCR, Associate, Accounting, Plasma, RAS, Investment, Patient, RUNX1, Clinical, LYN, TP53, DNMT3A, SYK, European Hematology Association, Research, Aplastic anemia, MRD, BCL2, PLOS One, MLL, Data, FLT3, TSX, Amylin Pharmaceuticals, FDA, Combination, RSK, Lymphoid leukemia, Absorption, BTK, Acute myeloid leukemia, Phase 1, CR, Hand, MD Anderson Cancer Center, Inflammation, Lymphoma, Phosphorylation, National university, NPM1, Clinical trial, European School, Data monitoring committee, AML, BID, EHA, ISTA Pharmaceuticals, Harvard Business School, Toxic leukoencephalopathy, G3, Gene, Society, Pharmaceutical industry, Cryptocurrency, Vaccine, Running

SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021.
  • Total cash and cash equivalents and investments as of December 31, 2022, were $47.0 million.
  • Aptose Appoints VP, Controller – During the fourth quarter, Aptose appointed Brooks Ensign, Vice President and Controller.
  • A summary of the results of operations for the years ended December 31, 2022 and 2021 is presented below:

Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

Retrieved on: 
Lundi, janvier 30, 2023
AML, Gene, BCL2, Society, ASH, NRAS, ITD, MLL, TSX, Mutation, SYK, Aplastic anemia, Toxic leukoencephalopathy, Patient, SAN, Clinical trial, NPM1, FDA, MD Anderson Cancer Center, KRAS, RUNX1, TKD, Acute myeloid leukemia, APS, TP53, FLT3, Toxicity, Maintenance, Associate, TKI, Pharmaceutical industry, Vaccine, DNMT3A

SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML). In parallel, another clinical response has been achieved by a R/R AML patient receiving 40 mg tuspetinib once daily orally in the original dose exploration trial, the second response at the recently launched low-dose 40 mg cohort.

Key Points: 
  • SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML).
  • Importantly, Aptose has elucidated a rationale for the superior safety profile of tuspetinib.
  • In the APTIVATE expansion trial, tuspetinib also will be tested in combination with venetoclax.
  • “We are pleased to have dosing underway in our APTIVATE clinical trial of tuspetinib in a very ill R/R AML population,” said William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer.

Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Retrieved on: 
Mercredi, janvier 4, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Hematology, Weakness, MF, Anemia, Food, TI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, LFT, Peripheral edema, DNMT3A, Diarrhea, NDA, ESA, Reverse transcriptase, Risk, Cytopenia, Disease, ASXL1, Patient, Imetelstat, IWG, Febrile neutropenia, Infection, Mutation, Brain Quest Grades 3 & 4, Safety, Marketing, Neutropenia, Headache, MAA, Thrombocytopenia, MDS, TET2, Fast Track, Pharmaceutical industry, EU

Imetelstat patients also experienced a statistically significant (p=0.042) and clinically meaningful mean reduction in RBC transfusion units compared to placebo.

Key Points: 
  • Imetelstat patients also experienced a statistically significant (p=0.042) and clinically meaningful mean reduction in RBC transfusion units compared to placebo.
  • “The notable results from IMerge Phase 3 underscore our belief that, with the unique mechanism of action of imetelstat as a telomerase inhibitor, the drug has the potential to become a first-in-class therapy for lower risk MDS patients.
  • “The IMerge Phase 3 efficacy results illustrate the depth, breadth and durability of transfusion independence potentially achievable with imetelstat treatment, which could be practice changing, if approved.
  • A conference call with Geron management to review the IMerge Phase 3 top-line results is scheduled at 8 a.m. Eastern Time this morning and may be accessed on Geron’s website.

Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

Retrieved on: 
Dimanche, décembre 11, 2022
Associate, NRAS, HSCT, Absorption, MLL, ASH, Infrared spectroscopy correlation table, FLT3, RUNX1, AML, Toxicity, ITD, Gene, Research, PR, COVID-19, KRAS, Clinical trial, Aplastic anemia, Safety, Bone marrow, B-cell lymphoma, Drug development, Risk, MRD, TSX, Solar cycle 22, Society, Plasma, CRC, Hematology, APS, SYK, JAK, Animal, BID, TP53, Exchange, BTK, Prior, Patient, MD Anderson Cancer Center, NPM1, GMP, AES, Toxic leukoencephalopathy, CR, Acute myeloid leukemia, TKD, G1, DLBCL, Pharmaceutical industry, Dietary supplement, Generic drug, DNMT3A, G3

“The welcome blend of safety and breadth of activity seen with tuspetinib in AML patients makes this an ideal candidate for combination therapy,” remarked Dr. Daver.

Key Points: 
  • “The welcome blend of safety and breadth of activity seen with tuspetinib in AML patients makes this an ideal candidate for combination therapy,” remarked Dr. Daver.
  • Prior to Aptose licensing tuspetinib, Hanmi Pharmaceutical Company demonstrated complete remissions at the 80 mg dose level.
  • As of January 1, 2022, Aptose assumed control of clinical trial activities and has demonstrated additional complete remissions at the 120 mg, 160 mg, and now the 40 mg dose levels.
  • Vignettes of patient experiences highlight the potency and breadth of tuspetinib to deliver complete remissions among several mutationally-defined populations with a diversity of adverse mutations.

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

Retrieved on: 
Samedi, décembre 10, 2022
Mixed-phenotype acute leukemia, Neoplasm, Incidence, Security (finance), KURA, DNMT3A, Acute leukemia, ASH, FLT3, AML, QT interval, Toxicity, Research, Food, FDA, Safety, Cancer, Bone marrow, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRD, Duke Cancer Institute, IDH, Society, FTI, Therapy, Breakthrough therapy, CRH, KMT2D, News, HRAS, Venetoclax, Element, Disease, Patient, DS, NPM1, CT, Prognosis, Optimus, CR, Survival, Orphan, IND, HNSCC, Risk, Postcholecystectomy syndrome, Pharmaceutical industry, KMT2A

SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical data from KOMET-001, a Phase 1/2 trial of the Company’s potent and selective menin inhibitor, ziftomenib, including an encouraging safety and tolerability profile and clinical activity in patients with relapsed/refractory acute myeloid leukemia (AML).

Key Points: 
  • These data are being featured during an oral session today at the American Society of Hematology (ASH) Annual Meeting.
  • The patient entered the trial having progressed through seven prior lines of therapy and remains on ziftomenib after two years.
  • ET today, December 10, 2022, following the oral presentation of updated data from the KOMET-001 clinical trial at the ASH Annual Meeting in New Orleans.
  • Ziftomenib, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) in patients with NPM1-mutant and KMT2A-rearranged AML.

Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDS

Retrieved on: 
Lundi, décembre 12, 2022
Software, Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Other Science, Leukemia Research, HOXA9, Lymphatic system, CEBPA, Software, Biosimulation, Society, Research, Methylation, Disease, Patient, DS, SPI1, Pearson, EZH2, Myelodysplastic syndrome, AML, MDS, Drug combination, Prognosis, Decitabine, City, University of Tennessee Health Science Center, University, DNMT3A, Abstract, Survival, NR, R, MD, Leukemia, Diagnosis, CBL, CBM, UnitedHealth Group, Student, TP53, Sequoia Capital, HMA, ASH, Versata Development Group, Inc. v. SAP America, Inc., Master of Science, Exposition, Chair, NF1, ITGAM, Haematopoietic system, Biomarker, RUNX1, Neuro, GATA1, Blood, Hypomethylating agent, NRAS, Medical imaging, Pharmaceutical industry, Hematology

In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).

Key Points: 
  • In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).
  • This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS patients.
  • This study shows that Cellworks personalized therapy biosimulation, which was based on each patients genomic aberrations, reveals a high spectrum of DS among patients with MDS.
  • The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology.